The fiber-modified adenoviral vector D-24-RGD (D24RGD) offers vast therapeutic potential. Direct injection of D24RGD has been used to successfully target ovarian tumors in mice. However, systemic toxicity, especially in the liver, profoundly limits the efficacy of direct viral vector delivery. Mesenchymal stem cells (MSC) have the ability to function as a vector for targeted gene therapy because of their preferential engraftment into solid tumors and participation in tumor stroma formation. We show that MSC-guided delivery of D24RGD is specific and efficient and reduces the overall systemic toxicity in mice to negligible levels compared with D24RGD alone. In our model, we found efficient targeted delivery of MSC-D24RGD to both breast and ovarian cell lines. Furthermore, immunohistochemical staining for adenoviral hexon protein confirmed negligible levels of systemic toxicity in mice that were administered MSC-D24RGD compared with those that were administered D24RGD. These data suggest that delivery of D24RGD through MSC not only increases the targeted delivery efficiency, but also reduces the systemic exposure of the virus, thereby reducing overall systemic toxicity to the host and ultimately enhancing its value as an anti-tumor therapeutic candidate.
Introduction
Adenovirus, a DNA tumor virus, is able to infect and replicate in quiescent cells because viral proteins (vp) induce S-phase entry. The most efficient progression from G1 into S-phase requires binding and inactivation of the retinoblastoma protein family of proteins by the adenovirus E1A early vp. This interaction requires amino acids 122-129 of the E1A protein conserved region 2. Mutations within this domain result in a loss of transformation by E1A without inhibiting its transactivation function. 1 For adenovirus serotype 5 (Ad5), coxsackie-adenovirus receptor (CAR) expression is the major factor determining infectivity. Evidence suggests that the expression level of CAR is often low in primary ovarian cancer cells 2 and in mesenchymal stem cells (MSC). 3 To overcome low expression levels and thus increase infection in MSC, and subsequently in ovarian carcinoma, the fiber of Ad5-D-24-RGD (D24RGD) was modified by incorporating the arginine-glycine-asparatate (RGD)-4C motif into the HI loop, to allow for integrin binding. This infectivity enhancement has previously been shown to dramatically increase the transduction of ovarian cancer cells. 4 Moreover, because most ovarian cancer patients present with ascites, the RGD-4C modification allows partial escape from neutralizing antibodies regularly present in the ascites. 4 D24RGD has been used as a therapy for many types of tumors, [5] [6] [7] including ovarian tumors, 8 through direct injection of the virus. Direct injection of the D24 virus alone has resulted in increased survival in ovarian carcinoma mouse models, but it causes significant systemic toxicity, especially in the liver.
Numerous studies have shown that the inadequacy of viral vector gene delivery is due to the systemic toxicity induced in the host. Even when locally injected into the tumor site-an application that is not possible in all cancers-viral dissemination still occurs. [9] [10] [11] The high toxicity levels render this therapeutic method ineffective in potential nontopical clinical applications; however, as we will show, using MSC as a delivery vehicle abrogates viral dissemination and reduces systemic toxicity to negligible levels.
Mesenchymal stem cells have vast potential for clinical use. They contribute to the maintenance and regeneration of various connective tissues and can be obtained from bone marrow, expanded in vitro and genetically modified for therapy. Their in vivo engraftment depends on the appropriate external signals from the tissue microenvironment. It has been shown that tumors provide the local environmental signals-closely resembling wound healing and tissue repair signals-that can mediate MSC engraftment. [12] [13] [14] [15] We originally showed the preferential engraftment of MSC into solid tumors and their participation in tumor stroma development; subsequently, we and others have shown the efficacy of tumor engraftment by MSC. 11, [16] [17] [18] Mesenchymal stem cells enhance the therapeutic value of viral vector-mediated gene therapy in two ways. First, they enhance the targeting specificity of the conditionally replicating D24RGD to the localized tumor environment, thereby theoretically increasing the therapeutic index by selectively replicating within tumor tissue, 19 resulting in efficient tumor penetration and amplification of the antitumor effect. This ability has been shown by other investigators in a number of different cancer models. 18 Second, the use of MSC substantially reduces the systemic toxicity and viral dissemination that occurs during standard D24RGD treatment. Adenoviral gene therapy through MSC delivery is a safe and superior therapeutic application for aggressive cancer therapies, and it need no longer be limited to localized intratumoral injections as it can be administered intraperitoneally.
The efficiency of MSC delivery of adenovirus to tumors has been analyzed previously in ovarian and lung metastases animal models and glioma animal models. 12, 18, 20, 21 Contrary to Hakkarainen et al. 22 who were unable to show MSC-tumor tropism, we are able to show MSC-tumor tropism with our D24RGD-loaded MSC that enhances the specificity of viral delivery and safeguards against the systemic toxicity observed in trials using viral vectors alone.
In an effort to overcome the systemic toxicity initiated by high-titer adenoviral treatments, mammalian cells have been explored as delivery vehicles. Gene delivery vectors must possess several characteristics to be considered clinically applicable. To date, several cells have been examined as potential vehicles, including hematopoietic stem cells, 23 fibroblasts, 24 keritinoctes 25 and myoblasts, 26 in an attempt to overcome the immunological barriers to direct administration of viral vectors, including rapid degradation (immune clearance) and high toxicity. 18, 27 MSC are an attractive tool for the delivery of anticancer agents to tumors because of their selective engraftment in injured or regenerating tissues, such as tumors. 15 In our in vivo mouse model, we show that the delivery of D24RGD through MSC increases the targeted delivery efficiency and reduces the overall systemic toxicity to the host using in vivo imaging, histology and immunohistochemical staining.
Materials and methods

Cell isolation and culture
Human MSC were isolated as previously reported. 12 Human ovarian cancer SKOV-3, OVCAR-3 and HEY cells were cultured as previously described, 28 as were human breast cancer MDA231 and melanoma A375SM cell lines. 17 Human kidney fibroblast 293S cells were a gift from Dr Richard Cristiano (Department of Genitourinary Oncology, MD Anderson Cancer Center, Houston, TX). The cells were maintained in Dulbecco's modified Eagle's medium (D-MEM) supplemented with 10% fetal bovine serum, L-glutamine and penicillin-streptomycin mixture (Gibco/Invitrogen, Carlsbad, CA).
Adenoviruses
Green fluorescent protein-tagged adenovirus (GFP) was created in our laboratory as reported previously. 29 The replication-competent Ad5-D24RGD adenovirus was provided by Juan Fueyo (The University of Texas MD Anderson Cancer Center). This virus contains a 24-nucleotide deletion from Ad5 bp 923 to 946 (both included) that corresponds to the amino acid sequence L 122 TCHEAGF 129 of the E1A protein and is known to be necessary for retinoblastoma protein binding. 28 Details of the tumor-specific replication of this virus have been presented elsewhere. 30 D-24RGD also contains recombinant RGD fiber. In brief, an E1 fragment containing the 24-bp Ad5 deletion was isolated from the plasmid pXC1-D24 (originally used to construct D24) 30 and cloned by homologous recombination into the ClaI-digested plasmid pVK503 containing the RGD fiber. The genome of the new virus was released from the plasmid backbone by digestion with PacI, and the resulting fragment was used to transfect 293 cells to rescue Ad5-D24RGD. Details of this process have been published elsewhere. 31 The control virus used throughout this experiment was ultraviolet (UV)-inactivated D24RGD (UVD24RDG). It was prepared as follows: D24RGD was diluted 1:1000 in serum-free a-MEM, irradiated on ice eight times with 125 ml and then used immediately.
Mesenchymal stem cell (MSC) replication
Mesenchymal stem cells were plated at 20 000 cells per well in a six-well plate (Becton Dickinson, Franklin Lakes, NJ). Every 24 h, one well was washed with phosphate-buffered saline, and cells from that well were lifted with Trypsin-EDTA (Gibco), counted 10 times on a hemacytometer and the average number determined.
D24RGD replication in mesenchymal stem cells (MSC)
Mesenchymal stem cells were plated at 100 000 cells per well in a six-well plate (Becton Dickinson). Then, 24 h later, MSC were infected for 2 h in serum-free medium (a-MEM) at 37 1C in 5% carbon dioxide with increasing concentrations of D24RGD. After 48 h, cells were stained with crystal violet (0.2% in 10% phosphate-buffered formalin) for 1 h. The wells were then washed with water and allowed to dry, and photographs were taken at Â 4 magnification. Imaging was performed with a Zeiss Axioplan2 microscope (Carl Zeiss Inc., Thornwood, NY) equipped with a charge coupled device camera (Hamamatsu Corp., Bridgewater, NJ) and Adobe Photoshop software (Adobe Systems Inc., San Jose, CA). D24RGD replication in MSC was confirmed by the detection of hexon protein levels (IDEIA kit, dakocytomation). Burst size data, measuring the viral replication in one round of MSC replication, was measured after 24 h of MSC replication. In brief, 24 h after MSC were plated at 250 000 cells per 10-cm dish, MSC were infected for 2 h with D24RGD at an increasing multiplicity of infection. After 24 h, the MSC were trypsinized, spun down and resuspended in Tris-EDTA buffer (10 mM) before being freeze-thawed thrice. DNA was extracted with phenolchloroform -isoamyl alcohol, washed in 100% ethanol and resuspended in water before being analyzed by realtime PCR (ABI-7900) using Sybr-green super mix (BioRad, Hercules, CA) and E1a primers. E1a expressed was standardized against diluted concentrations of pure virus titer at known concentrations and expressed as viral particles per microliter.
Mesenchymal stem cell (MSC)-D24RGD in ovarian cell lines
Mesenchymal stem cells were plated at 100 000 cells per well in a six-well plate (Becton Dickinson). Then, 24 h later, MSC were infected for 2 h in serum-free medium (a-MEM) at 37 1C in 5% carbon dioxide with increasing concentrations of D24RGD. Wells were then washed thrice with phosphate-buffered saline and the medium (a-MEM and 20% fetal calf serum) was replaced. Supernatants were collected after 48 h and applied to OVCAR-3 and SKOV-3 cells (initially plated at 50 000 cells per well in a 12-well plate 24 h earlier). Results are shown as viable cells (percentage of control) after 72 h and were determined using Trypan blue cell counts.
Mesenchymal stem cell (MSC)-D24RGD in multiple cell lines
Mesenchymal stem cells were plated at 100 000 cells per well in a six-well plate (Becton Dickinson). Then, 24 h later, MSC were infected for 2 h in serum-free medium (a-MEM) at 37 1C in 5% carbon dioxide with 50 vp per cell of D24RGD. Wells were then washed thrice with phosphate-buffered saline and the medium (a-MEM and 20% fetal calf serum) was replaced. Supernatants were applied 72 h later to OVCAR-3, SKOV-3, HEY, A375sm (melanoma), MDA231 (breast cancer) or 293S cells (initially plated at 300 000 cells per well 24 h earlier). Cells were photographed at 24 and 48 h after the application of the MSC-D24RGD supernatants. After 48 h, cells were stained with crystal violet (0.2% in 10% phosphate-buffered formalin) for 1 h. The wells were then washed with de-ionized water and allowed to dry, and photographs were taken at Â 4 magnification.
Mice, cell administration, tumors and survival analysis Female CB-17 severe combined immunodeficient mice were purchased from Harlan (Indianapolis, IN). Mice were used in accordance with the institutional guidelines under approved protocols. Cells were administered as a suspension in 1 ml of phosphate-buffered saline. Mice were injected intraperitoneally with 4 Â 10 6 SKOV-3 cells (day 0). Then, 12 days later, treatments began that consisted of 4 weekly injections of either 1 Â 10 6 MSC-D24RGD (50 vp per cell D24RGD, n ¼ 21), MSC-green fluorescent protein GFP (3000 vp per cell, n ¼ 10), MSC alone (n ¼ 5) or MSC-UVD24RGD (50 vp per cell, n ¼ 5). One control group received no treatments (n ¼ 4). Survival was measured as the day of tumor cell injection until the day of death. Differences in survival were determined using a two-tailed log-rank test. Statistical analysis was performed using Statistica software (StatSoft Inc., Tulsa, OK).
Tissue processing and imaging studies Tumors and other organs were embedded in OTC compound (Miles, Inc., Elkhart, IN) and then snapfrozen in liquid nitrogen and stored at À80 1C. The frozen tissue was sectioned (6-8 mm) and processed for hematoxylin-eosin or hexon immunohistochemical staining. The appropriate slides were also checked for the presence of green fluorescent protein.
Immunohistochemical analysis Adenoviral hexon protein was detected in tumor xenografts using frozen sections of mouse tumors. Sections were fixed for 5 min in neutral buffered formalin, and then endogenous peroxidase activity was quenched by incubating the sections in 0.3% hydrogen peroxide in methanol for 30 min. The sections were treated with goat anti-hexon antibody (diluted 1:1000; Chemicon, Temecula, CA). Peroxidase substrate (Vector Laboratories, Burlingame, CA) was developed using an 3-amino-9-ethylcarbazole substrate kit (Vector Laboratories). Slides were then counterstained with hematoxylin QS (Vector Laboratories), and aqueously mounted with aqueous mounting medium (low viscosity) (Scytek Laboratories, Logan, UT).
Results
Replication of D24RGD in mesenchymal stem cells (MSC)
The D24RGD replication pattern closely resembles that of the MSC growth curve (Figure 1 ). D24RGD replication in MSC was confirmed by the detection of hexon protein levels (Figure 2 ) in the MSC supernatant over a 6-day period. The increase in hexon protein correlates with replication of the virus in MSC. MSC-D24RGD showed evidence of a cytopathic effect within 48 h compared with UV-irritated controls after infection with 5, 50, 500, 1000 or 2500 vp per cell (Figure 2 ). D24RGD replication in MSC was confirmed by the detection of E1a expression levels in the MSC after one round of replication. The E1a expression was quantified by real-time PCR using known, sequentially diluted concentrations of pure virus as standard curve. E1a expression in infected MSC was graphed as viable vp produced per cell, or burst size (Figure 2d ).
Mesenchymal stem cell (MSC)-D24RGD effects on multiple cell lines
The 72-h supernatant from D24RGD-infected MSC (50 vp per cell) was applied to six different cell lines: A375sm, MDA231, HEY, SKOV3, OVCAR-3 and 293S. Within 24 h, a cytopathic effect was evident in all cell lines, and progressive amplification continued through 48 h. The shown cytopathic effect is consistent with efficient replication. These data confirm that not only does D24RGD replicate in MSC, but the viable virus can infect, replicate in and lyse target cells in vitro (Figure 3) .
We also counted cell death by measuring cell viability of two human ovarian carcinoma lines, OVCAR-3 and SKOV-3, after 72 h of incubation with supernatants from MSC-D24RGD that had been conditioned for 48 h previously (Figure 4) . The decrease in cell number is inversely proportional to the titer of virus used to infect the MSC. Because D24RGD replicates in these tumor cells, as the length of the assay increased, the number of viable cells decreased (data not shown).
Mesenchymal stem cell (MSC)-D24RGD as treatment for ovarian carcinoma in vivo
Thus, MSC-D24RGD (Po0.001) and D24RGD alone (Po0.001) nearly doubled the survival of mice, compared with survival of untreated control mice. The average increase in survival was 55 days (Figure 5a ). The other control groups-those receiving MSC-GFP (P ¼ 0.151), MSC (P ¼ 0.024) and MSC-UVD24RGD (P ¼ 0.096)-had no significant increase or decrease in survival time.
Although the increase in survival due to tumor burden using MSC-D24RGD was similar to that of using D24RGD alone, we hypothesized that using MSC to deliver the virus would allow for a targeted, local delivery of D24RGD to the tumor. This was determined through immunohistochemical analysis. The presence of the hexon staining within tumor sections is more evident in the MSC-D24RGD as opposed to the D24RGD in which the hexon staining is evident only around the outer edge of the tumor (Figure 5b ).
Systemic biodistribution
To determine the systemic dispersion of virus, SKOV-3 severe combined immunodeficient mice were injected intraperitoneally with either MSC-D24RGD (50 vp per cell, n ¼ 3) or D24RGD (5 Â 10 7 vp per mouse, n ¼ 3). Immunohistochemical analysis of tissues from mice after 1 or 3 days showed significant differences in the diffusion of hexon (Figure 6 ). Intraperitoneal injections of the virus alone resulted in a more systemic distribution of virus. At 1 day after injection of virus, both the muscle behind the tumor and muscle in the opposite limb had hexon-positive spots, as did the spleen, kidney and liver. It should be noted that the liver had many more positive spots. In addition, inclusion bodies can be found in hematoxylineosin-stained sections of the livers of mice treated with D24RGD alone (data not shown). Hexon protein positivity is evidence of viral infection and leads to systemic toxicity that can be deadly. We did not observe high levels of hexon staining in any tissues, and mild staining was observed in the MSC-D24RGD-treated group. Tissues examined 1 day after MSC-D24RGD injection were negative, except for a few small spots in the liver ( Figure 6a ) compared with tissues from D24RGD-treated mice (Figure 6b ). By day 3, the D24RGD-treated groups showed decreased hexon staining (Figure 6d) , and MSC-D24RGD-treated tissues remained negative for hexon, with the exception of the liver, which showed a decrease in staining from the day 1 sample (Figure 6c ). Foci quantitation of the hexon-stained tissue highlights the minor presence of the virus in the liver (indicator of systemic toxicity) of MSC-D24RGD-treated mice (Figure 7) . These data show the ability of MSC to locally deliver D24RGD to the tumor microenvironment with a dramatic decrease in systemic spread compared with the use of D24RGD alone.
Discussion
Ovarian cancer usually presents at an advanced stage, typically with peritoneal metastasis, which has the worst prognosis among ovarian cancer metasases. Gene therapy trials published thus far have used intraperitoneal administration for treatment. This can be conveniently achieved with a catheter, and the peritoneal cavity allows a degree of compartmentalization. However, we show that the systemic spread that occurs after intraperitoneal injection of D24RGD used alone is highly toxic. We have shown toxicity to be the limiting factor in the value of D24RGD for treatment of peritoneally disseminated ovarian cancer when used without a delivery vehicle. In a recent study, adenovirus alone, even when directly injected into the tumor site, was ineffective, even though it had an anti-tumor effect, because of the shortened survival attributed to liver toxicity caused by viral dissemination. 11 We show the use of MSC as delivery vehicles for anticancer therapy in an attempt to overcome the immunological barriers to direct administration of viral vectors, including rapid degradation (immune clearance) and high systemic and organ toxicity. 18, 27 MSC are also easily transduced with viral vectors (for example, adenovirus, retrovirus and adeno-associated virus) to express high levels of transgene product that can be maintained over several passages and through differentiation.
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D24RGD is cell-cycle dependent (similar to other conditionally replicative adenoviruses), and can therefore replicate when the cell is actively dividing (the S phase). Although it has been shown that replication of conditionally replicative adenoviruses is greater in proliferating normal cells than in matched, nonproliferating normal cells, it is important to note that the replication in the proliferating normal cells is still several orders of magnitude less than that observed in cancer cells. 1 MSC growth closely resembles the viral replication curve (Figure 1) , implying that the MSC are adequate replication vehicles. In addition, the self-renewable MSC can be extensively expanded in culture and are able to undergo site-specific differentiation by taking signals from their immediate environment, without any evidence of ectopic tissue formation. 33, 34 We have shown that MSC support D24RGD replication in vitro, and 3-day supernatants of MSC-D24RGD (50 vp per cell) were able to infect and lyse OVCAR-3, SKOV-3 and a number of other tumor cell lines. Our in vivo studies were conducted to target established ovarian carcinoma tumors through intraperitoneal administration of MSC-D24RGD (4 injections, 1 per week), and we found a survival benefit (Pp0.0001) over that of MSC delivery of the UVD24RGD control virus.
Replication and subsequent oncolysis were measured through hexon (replication) levels and viable cell counts, respectively (Figure 2 ), and we found that the virus was able to replicate within cells. In vivo, cell turnover and viral dispersion dynamics are likely to be different because of the natural milieu of the host, including the threedimensional nature of solid tumors. However, trends similar to those in our in vitro studies were observed in mice that were administered intraperitoneal injections of MSC-D24RGD ( Figure 5 ). Importantly, we found that using MSC to deliver D24RGD not only successfully achieved a targeted gene delivery that increased the infection of tumor cells over cells infected with D24RGD alone, but also limited the systemic spread of the virus. The decreased tumor burden in the mice receiving D24RGD or MSC-D24RGD were both significant when compared with tumor alone. However, the decrease in tumor burden was comparable between the mice that were administered D24RGD and those that were administered MSC-D24RGD ( Figure 5 ), but the overall systemic toxicity was significantly decreased in mice receiving the MSC-D24RGD injections ( Figure 6 ). Although it is understood that the human adenovirus does not replicate as efficiently in mouse tissues as it does in human tissues, there are still significant amounts of hexon staining in the liver, kidney, spleen and even muscle that is not observed in the MSC-delivered D24RGD ( Figure 6 ). With this in mind, the systemic toxicity of the adenovirus is assumably higher, and thus the effectiveness of the MSC delivery system may be even greater. Similar to previous studies, 35 we have achieved a targeted delivery system using MSC as a vector to selectively distribute D24RGD to the tumor microenvironment and significantly increase survival in severe combined immunodeficient mice with SKOV-3 ovarian carcinoma. More importantly, we were able to overcome a major hurdle in the viral gene therapy field: systemic toxicity. Using MSC as a 'Trojan horse', we were able to limit the systemic distribution of the virus and evade the host innate immune response. Evasion of viral dissemination and overall systemic toxicity of the adenovirus through the use of MSC as a delivery vehicle is a significant finding in the advancement of cancer gene therapy and facilitates the progression of clinical trials that have been thwarted by the toxic side effects of viral vector therapeutic agents. showed the least systemic toxicity, which was limited to the liver.
